All In Biotech

Drug Trial Radar · NCT05772104

Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder

A Multi-center, Randomized, Double-Blind Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder

Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 495 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

495

Planned (sponsor's estimate)

Start

Apr 17, 2023

Primary completion

Feb 28, 2025

Study completion Jun 1, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized double-blind placebo-controlled phase 3 clinical trial to further validate the effectiveness and safety of Shugan Jieyu Capsules in treating generalized anxiety disorder.

Conditions

  • Generalized Anxiety Disorder

Interventions

  • Shugan Jieyu CapsulesDrug

    Oral, 4 Capsules, BID

  • Shugan Jieyu Capsules PlaceboDrug

    Drug: Shugan Jieyu Capsules Placebo, Oral,4 capsules,BID Drug: Placebo, Oral, 1 capsule, BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the HAM-A Total Score at Week 12Time frame: Change from Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anding Hospital Affiliated to Capital Medical University

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.